Thanks to advances in treatment, approximately 85-90% of patients suffering from Wilms' tumour are now cured. However, success rate after relapse is significantly lower, ranging from 25 to 45%. Several different re-induction approaches, more or less intensive according to first-line therapy and characteristics of relapse, have been proposed. A number of adverse prognostic factors related to a bad outcome after relapse have been identified and are used as inclusion criteria for entering in a programme including high-dose chemotherapy (HCT). HCT followed by autologous haematopoietic stem cell rescue has been used in small numbers of patients worldwide and promising results have been reported. Information from the European Group for Blood and Marrow Transplantation Database regarding more than 300 transplants have been gathered. In addition, literature data on rescue therapy and HCT will be discussed, such as recent treatment proposals currently under discussion within European and US cooperative groups.
Introduction
Wilms' tumour (WT) is a highly curable childhood cancer, the success rate of which is approximately 80-85% with conventional treatment based on vincristine, dactynomicine, surgical removal of the primary tumour and, in selected cases, the addition of doxorubicin and radiotherapy. 1 Relapse is often related to a poor outcome, and for patients bearing some adverse prognostic factors (APFs), event-free survival (EFS) is less than 15%. 2, 3 Some different approaches have been investigated to treat this small cohort of children, including re-treatment with the same drugs, 4 new combinations such as ifosfamide plus etoposide plus carboplatin (ICE) 5, 6 and final consolidation with high-dose chemotherapy (HCT) and autologous progenitor cells rescue. [8] [9] [10] [11] Indications and risk factors
Owing to the small number of patients suffering from relapse, no clear indications to HCT exist. Nevertheless, looking at the experiences reported in the international literature, the majority of the patients in which HCT and autologous progenitor cells rescue has been used are in second complete (CR2) or partial remission (PR). To our knowledge, there are no published data that analyse in depth the consolidation with HCT in patients in CR1 (CR1 patients were those who were initially resistant to first-line chemotherapy but reached CR1 with a second-line treatment). The French and US groups had defined the presence of some APFs at relapse to be strictly correlated with a poor outcome. APFs are relapse, progression or incomplete response of initial stage IV, second or subsequent relapse, relapse within the radiation field, bone or brain metastases, early relapse (o6-12 months after nephrectomy), relapse of tumour with unfavourable histology and extraregional lymph node involvement. On the contrary, no risk factor for post-HCT outcome has been recognized, even though in some reports patients transplanted with measurable disease (that is second PR or minor response) show a worse prognosis. Unpublished data regarding the Italian patients suggest a better prognosis in case of solitary pulmonary metastasis at relapse.
Results
Up to now, very few papers regarding the use of HCT in patients with WT having poor prognosis have been published. The first report was by Garaventa et al. 7 about 25 children enrolled in the European Group for Blood and Marrow Transplantation (EBMT) database. EFS for the entire cohort was 34% (median follow-up 14 months). Eight out of 17 children transplanted in CR were alive and disease free (median follow-up 34 months). Concerns were raised for severe toxicity caused by lung radiotherapy (RT) after HCT. Kullendorf and Bekassy 8 reported that two out of four children were alive in CR after HCT. In 1998, the French experience on 29 patients with relapsed WT was published. 9 Preparative regimen was MEC (melphalan 180 mg m À2 for 1 day, etoposide 200 mg m À2 day À1 for 5 days and carboplatin at a daily targeted area under the concentration-time curve of 4 mg Â min per ml for 5 days).
Disease-free survival and overall survival at 3 years were 50 ± 17 and 60 ± 18%, respectively. Grade III and IV haematological and non-haematological toxicity occurred in a great percentage of patients, notably renal disorders (n ¼ 8) and pneumonitis (n ¼ 3). Kremens et al. 10 in 2002 published data on 23 patients treated with HCT, the majority of them receiving MEC as a conditioning regimen. EFS was 48.2% and besides the haematological toxicity even six cases of renal function impairment (transient in 5) were observed. To our knowledge, the last experience in this field is by Campbell et al.,
11 who described 13 children who received one or two HCTs following various preparative regimens, mostly based on thiotepa. EFS at 4 years is 60% and a favourable role of CR before HCT is suggested. During the EBMT Paediatric Disease Working Party and International Society of Paediatric Oncology (SIOP) joint meeting held in Geneva in September 2006, data on 305 WT patients enrolled in the EBMT Solid Tumours database were presented.
In summary, in the period 1985-2005, 343 transplants in 305 patients have been reported to the Registry. Median age at transplant was 6 years (range 1-18) and the status of disease before HDC was CR2 (n ¼ 115), CR1/very good PR (n ¼ 53), sensitive relapse (SR, n ¼ 51), stable disease-PR (n ¼ 19) and resistant or untreated relapse (n ¼ 24). Several preparative regimens were given, mostly containing melphalan (MEC n ¼ 56, melphalan alone n ¼ 30, plus other drugs n ¼ 41). Overall survival for the patients transplanted in CR2 was 40%. Two very interesting cohorts include CR1 and SR patients (SR patients were the ones who showed some extent of response after relapse, but never reached CR, and were transplanted with measurable disease). Overall survival of these two groups was 71 and 34%, respectively. An analysis of these patients is ongoing to check accurately their long-term outcome.
The UK group is currently studying data on 42 patients suffering from relapsing WT and candidate to HCT. Analysis is in progress and no information is still available.
In the period 1991-2005, 59 children with poor-risk WT were transplanted in Italy and their data are available. Considering the small number of patients, the observation that those with relapse only in the lung and transplanted in CR2 seem to have a better outcome when compared with CR2 patients relapsing in the abdomen high population heterogeneity should be considered with caution. On the contrary, no clear conclusions can be drawn regarding preparative regimen and the role of status at transplant. On these bases, a prospective protocol proposal was subsequently set up (Figure 1 ). Between January 2001 and June 2006, 15 children who relapsed or had unresponsive disease were treated in Italy adopting an intensive-dose chemotherapy regimen (mostly with the ifosfamide/carboplatin/ etoposide association), followed by HCT (melphalan-based in all but one patient) and peripheral blood stem cell rescue in 13. 12 All but two children initially received doxorubicin as their first-line therapy and all had at least one adverse prognostic feature, with seven patients showing three or four. Currently, 10 children are alive in continuous remission after a median of 17 months from relapse (range 7-33 months). Four patients subsequently relapsed and eventually died of disease progression. One death was due to toxicity. Estimated disease-free survival, overall survival and EFS rates were 63±15, 59±16 and 58±14% at 2 years.
Children's Oncology Group (COG) group is studying the efficacy of ICE-T combination (ifosfamide þ carboplatin þ etoposide þ topotecan) in high-risk relapsing patient with HCT as the final consolidation. The hypothesis of an SIOP/ COG cooperative study that compares prospectively ICE versus ICE-T in the re-induction phase and standard therapy versus HCT in the consolidation is currently under evaluation by the respective study groups.
Conclusions
The starting point is that relapse in WT is infrequent and then randomized studies of treatment strategies for these patients are not easy to perform and have never been conducted. A lot of questions remain unsolved:
1. Presence of APFs confers a bad prognosis on relapsing patients, but the impact of one or more APFs has not been defined. 2. Isolated pulmonary metastasis, in a lung not previously irradiated, can have a better prognosis, and HCT could be avoided, but published consistent data do not support this hypothesis. 3. Role and timing of RT has to be discussed. Even in a small number of patients, the message of the EBMT report 7 about the risk of fatal toxicity if RT was given immediately before HCT was quite clear. In addition, the efficacy and the cumulative toxicity of RT in a previously irradiated field has to be discussed on an individual basis with a panel of radiotherapists. 4. The best re-induction regimen should include drugs active against WT, as those reported in literature (AbuGosh, Pein), and doxorubicin, the latter if not given previously. The role of relatively new drugs (that is topotecan) should be investigated in very poor prognosis relapses and in patients not responding to first-line rescue treatment. 5. Nephrotoxicity of drugs such as carboplatin, diffusely used in the re-induction phase as in the conditioning regimen (MEC, reported by the French and Italian groups), and ifosfamide might be considered, and a frequent evaluation of renal function might be performed. 6. The achievement of CR before HCT should be profitable and, on the other hand, this is a concept well consolidated in HCT field. However, this raises the question on timing of HCT, number of cycles needed to obtain CR, cumulative toxicity and risk of drug resistance. EBMT database quotes several patients transplanted with measurable disease (PR or stable disease or SR) who reached CR with HCT. The outcome of this group has never been studied in detail and we believe it deserves special consideration in order to define general recommendations. If it is feasible, a comparison with patients treated without HCT would be very interesting. 7. Retrospective analysis is often inconclusive due to the wide range of treatments and of eligibility criteria adopted. In this context, the COG proposal of prospective multinational randomized trial of conventional chemotherapy versus HCT followed by autologous stem cells rescue is very interesting, although difficult to set up. Alternatively, oncologists should stress national groups to draw cooperative studies, including common enrolment criteria, induction therapy and high-dose preparative regimen.
